Dr Rupa Huq

Joe Biden’s recent diagnosis has to some extent put prostate cancer in the spotlight of late, but it is not just him—there is Stephen Fry, Jools Holland and Robert De Niro. More than 50,000 men in the UK and 1.4 million men worldwide are diagnosed with prostate cancer yearly, which is projected to double by 2040. With one in eight men diagnosed during their life, it is the most common male cancer. More than half of those men are pre-retirement age, such as the cyclist Sir Chris Hoy, who was diagnosed at 48, but 70-plus is the most common age. My late dad was 69 when he was diagnosed. He left this earth just shy of his 79th birthday in August 2014, so he had 10 years. It is often said that men die with prostate cancer, not of it. With my dad, it spread to bone cancer, but pneumonia was actually the cause of death on the certificate. I miss him every day. Treatment for prostate cancer has improved dramatically since then. One crucial breakthrough is the development of the drug abiraterone, a Great British success story discovered and initially developed in London at the Institute of Cancer Research. It is a shining example of British science leading the world and revolutionising advanced prostate cancer care.